Cardiome Pharma Corporation Company Profile (NASDAQ:CRME)

Cardiome Pharma Corporation trades on the NASDAQ under the ticker symbol "CRME."

Cardiome Pharma Corporation (NASDAQ:CRME) announced its earnings results on Tuesday, August, 8th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by $0.08. The firm had revenue of $5.75 million for the quarter, compared to analyst estimates of $6.88 million. Cardiome Pharma Corporation had a negative net margin of 110.95% and a negative return on equity of 78.51%. Cardiome Pharma Corporation's revenue for the quarter was down 2.5% compared to the same quarter last year. During the same period last year, the firm earned ($0.37) earnings per share. View Cardiome Pharma Corporation's Earnings History.

Cardiome Pharma Corporation is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Cardiome Pharma Corporation.

5 equities research analysts have issued 12-month price objectives for Cardiome Pharma Corporation's shares. Their predictions range from $3.50 to $10.00. On average, they expect Cardiome Pharma Corporation's stock price to reach $6.56 in the next twelve months. View Analyst Ratings for Cardiome Pharma Corporation.

Here are some recent quotes from research analysts about Cardiome Pharma Corporation stock:

• 1. Canaccord Genuity analysts commented, "Date and time of first dissemination: August 21, 2017, 09:42 ET Date and time of production: August 21, 2017, 09:42 ET Target Price / Valuation Methodology: Cardiome Pharma Corp. – CRME Discounted cash flow analysis supports an $8 valuation for CRME shares Our discounted cash flow (DCF) analysis leads us to a 12-month valuation of around $8/share for CRME, assuming continued progress on the Brinavess Canada and Xydalba launches along with a potential Trevyent launch in 2019. We estimate a weighted average cost of capital (WACC) of 11.2%, which assumes an 88% equity/total capital structure at a 10.3% cost of equity capital and a 12% debt/total capital structure at a 14% cost of debt. We use a long-term estimated tax rate of 22% and a terminal growth decline of 1% in our analysis. For cash management purposes, our analysis assumes an equity raise in 2H/17 but management has not publicly commented on the possibility of future capital raises. Risks to achieving Target Price / Valuation: Cardiome Pharma Corp. – CRME OUS payers and providers can be more difficult to predict – Given the relative lack of market data compared to the US coupled with a fragmented payer landscape, variability in physician training and standard of care modalities, and different preferences in patient populations in OUS markets, the marketability of a product in these environments can be more difficult to predict than in the US." (8/21/2017)
• 2. According to Zacks Investment Research, "Cardiome Pharma Corp. is a product-focused cardiovascular drug development company with two clinical drug programs focused on atrial arrhythmia (intravenous and oral dosing), and a pre-clinical program directed at improving cardiovascular function. " (8/11/2017)

Some companies that are related to Cardiome Pharma Corporation include Peregrine Pharmaceuticals (PPHM), MediWound (MDWD), VIVUS (VVUS), Alimera Sciences (ALIM), Opiant Pharmaceuticals (OPNT), KalVista Pharmaceuticals (KALV), Chiasma (CHMA), Cesca Therapeutics (KOOL), Tokai Pharmaceuticals (NVUS), Ocera Therapeutics (OCRX), Sonoma Pharmaceuticals (SNOA), Catalyst Biosciences (CBIO), Onconova Therapeutics (ONTX), Argos Therapeutics (ARGS), Auxilium Pharmaceuticals (AUXL), Baxalta (BXLT), Horizon Therapeutics (HPTX) and Ocera Therapeutics (TZYM).

Cardiome Pharma Corporation's management team includes the folowing people:

• W. James O'Shea, Independent Chairman of the Board
• William L. Hunter M.D., President, Chief Executive Officer, Director
• Justin A. Renz, Chief Financial Officer
• Sheila M. Grant, Chief Operating Officer
• David D. McMasters J.D., Corporate General Counsel
• David C. Dean, Chief Business Development Officer
• Jennifer Archibald CPA, Chief Business Operations Officer
• Hugues Sachot, Chief Commercial Officer
• Richard M. Glickman LL.D., Lead Independent Director
• Mark H.N. Corrigan M.D., Independent Director

Cardiome Pharma Corporation's stock is owned by many different of institutional and retail investors. Top institutional shareholders include WESTFIELD CAPITAL MANAGEMENT COMPANY LP (16.75%), Westfield Capital Management Co. LP (16.56%), Tamarack Advisers LP (5.64%), Stonepine Capital Management LLC (5.00%), AlphaOne Investment Services LLC (1.98%) and JPMorgan Chase & Co. (0.49%). View Institutional Ownership Trends for Cardiome Pharma Corporation.

Cardiome Pharma Corporation's stock was sold by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Tamarack Advisers LP and PNC Financial Services Group Inc.. View Insider Buying and Selling for Cardiome Pharma Corporation.

Cardiome Pharma Corporation's stock was acquired by a variety of institutional investors in the last quarter, including Westfield Capital Management Co. LP, AlphaOne Investment Services LLC and JPMorgan Chase & Co.. View Insider Buying and Selling for Cardiome Pharma Corporation.

Shares of Cardiome Pharma Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Cardiome Pharma Corporation stock can currently be purchased for approximately $2.18.